Sheppard Mullin Richter & Hampton LLP
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. 
Gilead Sciences, Inc.
A A A A A A A A A A A A A A A A A A A A C A A A A A A A A A A A A A A A A A A A A A A A A A A
A61K A61P A61P A61P A61P A61P A61P A61P A61P A61K A61P A61P A61P A61P A61P A61P A61P A61P A61P A61K C07D A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Jeffrey E. Peter A. Scott A. Zhongdong Sundaramoorthi Seung H. Jin-Ming Jianjun Jennifer R. Aaron C. Kevin S.
Kropf Blomgren Mitchell Zhao Swaminathan Lee Xiong Xu Lo Schmitt Currie